Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Initial experience with dabigatran etexilate at Auckland City Hospital.

Bell S, Nand J, Spriggs D, Young L, Dawes M.

N Z Med J. 2012 Feb 10;125(1349):105-7. No abstract available.

PMID:
22327149
2.

National prescribing data for dabigatran.

Metcalfe S, Moodie P.

N Z Med J. 2012 Mar 9;125(1351):97-105. No abstract available.

PMID:
22426616
3.

Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.

[No authors listed]

Med Lett Drugs Ther. 2010 Nov 15;52(1351):89-90. Review.

PMID:
21068702
4.

Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.

Wagenaar P.

Cardiovasc J Afr. 2011 Sep-Oct;22(5):283. No abstract available.

5.

[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].

Geisler T, Gawaz M.

MMW Fortschr Med. 2011 Apr 14;153(15):27-30; quiz 31. German. No abstract available.

PMID:
21667556
6.

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.

Ahmad Y, Lip GY.

Heart. 2012 Oct;98(19):1404-6. doi: 10.1136/heartjnl-2012-302101. Epub 2012 Jun 14. No abstract available.

PMID:
22698856
7.

Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.

Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM.

Thromb Haemost. 2010 Dec;104(6):1106-15. doi: 10.1160/TH10-10-0642. Epub 2010 Oct 21.

PMID:
20967400
8.

Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.

Bovio JA, Smith SM, Gums JG.

Ann Pharmacother. 2011 May;45(5):603-14. doi: 10.1345/aph.1P644. Epub 2011 May 3. Review.

PMID:
21540406
9.

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.

Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8. Review.

PMID:
22318514
10.

Anti-thrombotic trials in atrial fibrillation, the RELY study.

Aalbers J.

Cardiovasc J Afr. 2010 Sep-Oct;21(5):299. No abstract available.

11.

Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.

Avecilla ST, Ferrell C, Chandler WL, Reyes M.

Am J Clin Pathol. 2012 Apr;137(4):572-4. doi: 10.1309/AJCPAU7OQM0SRPZQ.

PMID:
22431533
12.

Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.

Belavic JM.

Nurse Pract. 2011 Sep;36(9):6-7. doi: 10.1097/01.NPR.0000403296.82092.fb. No abstract available.

PMID:
21857210
13.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skj√łth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

14.

Focus on 2010 ESC Congress: new ESC guidelines and data on dabigatran.

Aalbers J.

Cardiovasc J Afr. 2010 Sep-Oct;21(5):300-1. No abstract available.

15.

Periprocedural management of patients on dabigatran etexilate treatment.

Watanabe M, Qureshi AI, Siddiqui FM.

AJNR Am J Neuroradiol. 2011 Sep;32(8):E166. doi: 10.3174/ajnr.A2731. Epub 2011 Jul 14. No abstract available.

16.

Bleeding with dabigatran (Pradaxa).

[No authors listed]

Med Lett Drugs Ther. 2011 Dec 12;53(1379-1380):98.

PMID:
22173427
17.

South Africa enters a new era in stroke prevention.

Aalbers J.

Cardiovasc J Afr. 2012 Nov;23(10):573. No abstract available.

18.

At last, a RE-LYable alternative to warfarin for atrial fibrillation.

Hankey GJ.

Int J Stroke. 2009 Dec;4(6):454-5. doi: 10.1111/j.1747-4949.2009.00389.x. No abstract available.

PMID:
19930055
19.

Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.

Kuwauchi S, Watanabe S, Abe K, Yamasaki M, Ito J, Kawazoe K.

Ann Thorac Surg. 2013 Nov;96(5):1863-4. doi: 10.1016/j.athoracsur.2013.03.043.

PMID:
24182477
20.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082

Supplemental Content

Support Center